Abstracts tagged "Kidney"

Abstract Number: 1505 • ACR Convergence 2021
Inflammatory Dendritic Cell and Th17 Polarization in Mouse Model of Lupus Nephritis
Latha Prabha Ganesan¹, Noushin Saljoughian¹, James Turman¹, Murugesan Rajaram¹, Brad Rovin², Wael Jarjour¹ and Samir Parikh², ¹Ohio State University, Columbus, OH, ²Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: We have recently identified inflammatory dendritic cells (InfDC) in human lupus kidneys. These cells are over expressed in LN patients compared to healthy controls.…
Abstract Number: 1569 • ACR Convergence 2021
Effect of Elevated Serum Urate on Kidney Function: Analysis of a Randomized Controlled Trial of Inosine Supplementation
Nicola Dalbeth¹, Borislav Mihov¹, Angela Stewart¹, Gregory Gamble¹, Tony Merriman², David Mount³, Lisa Stamp⁴, Ian Reid¹ and Anne Horne¹, ¹University of Auckland, Auckland, New Zealand, ²University of Alabama at Birmingham, Dunedin, New Zealand, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Observational studies have reported that serum urate associates with development and progression of kidney disease. However, it is uncertain whether elevated serum urate directly…
Abstract Number: 332 • 2019 ACR/ARP Annual Meeting
Incident Gout After Renal Transplantation in Gout-naïve Patients: Large Database Analysis
Brian LaMoreaux¹, Megan Francis-Sedlak ¹ and Robert Holt ¹, ¹Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: Patients undergoing kidney transplantation are at increased risk for developing hyperuricemia and gout compared to the general population (generally attributed to the frequent use…
Abstract Number: 1677 • 2019 ACR/ARP Annual Meeting
Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?
Pauline Morel ¹, Alexandre Karras ², Raphael Porcher ³, Xavier Belenfant ⁴, Vincent Audard ⁵, Cédric Rafat ⁶, Guillaume Hanouna ⁷, Séverine Beaudreuil ⁸, Cédric Vilain ⁹, Aurélie Hummel ¹⁰, Benjamin Terrier ¹¹, Evangeline Pillebout ¹², Matthieu Groh ¹³, Romain Jouenne ¹⁴, Robin Dhote ¹⁵, Olivier Fain ¹⁶, Matthieu Ponsoye ¹⁷, Nicolas Noel ¹⁸, Nicolas Limal ¹⁹, Loïc Guillevin ¹¹, Luc Mouthon ¹¹ and Alexis Régent¹¹, ¹Cochin Hospital, Paris, France, ²Paris HEGP, Paris, France, ³Hotel Dieu Hospital, Paris, France, ⁴Service de néphrologie, Hôpital André Grégoire, 56 Boulevard de la Boissière Montreuil, France, Montreuil, Ile-de-France, France, ⁵Henri Mondor Hospital, Créteil, France, ⁶Tenon Hospital, Paris, France, ⁷Service de néphrologie, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri Huchard, Paris, France., Paris, Ile-de-France, France, ⁸Bicetre Hospital, Le Kremlin Bicetre, France, ⁹Service de néphrologie hémodialyse, Hôpital Ambroise Paré, APHP, 9 avenue Charles de Gaulle, Boulogne-Billancourt, France, Boulogne-Billancourt, Ile-de-France, France, ¹⁰APHP, Paris, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ¹²Service de néphrologie et transplantation, Hôpital Saint-Louis, AP-HP, 1 avenue Claude Vellefaux, Paris, France., Paris, Ile-de-France, France, ¹³Service de médecine interne, maladies systémiques, Hôpital Saint Louis, AP-HP, 1 avenue Claude Vellefaux, Paris, France, Paris, Ile-de-France, France, ¹⁴Service de médecine interne, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri Huchard, Paris, France, Paris, Ile-de-France, France, ¹⁵Service de médecine interne, Hôpital Avicenne, AP-PH, 125 rue de Stalingrad, Bobigny, France, Bobigny, Ile-de-France, France, ¹⁶Service de médecine interne, Hôpital Saint-Antoine, AP-HP, 184 rue du Faubourg Saint-Antoine, Paris, France, Paris, Ile-de-France, France, ¹⁷Service de médecine interne, Hopital Ambroise Paré, Boulogne-Billancourt, Boulogne-Billancourt, Ile-de-France, France, ¹⁸Service de médecine interne et immunologie clinique, Hôpital Bicêtre, AP-HP, 78 rue du Général Leclerc, Kremlin-Bicêtre, France, Kremil-Bicêtre, Ile-de-France, France, ¹⁹Service de médecine interne, Hôpital Henri-Mondor, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil, France, Créteil, Ile-de-France, France
Background/Purpose: Induction therapy for severe ANCA-associated vasculitides (AAVs) is based on the combination of glucocorticoids and cyclophosphamide (CYC) or rituximab (RTX). For patients with severe…
Abstract Number: 2733 • 2019 ACR/ARP Annual Meeting
Inhibition of Neutrophil Elastase Reduces Autoantibody Levels and Renal Inflammation in Murine Lupus
Gautam Sule¹, Kristen Gilley ¹, Andrew Fernandes ¹, Srilakshmi Yalavarthi ¹ and Jason Knight ², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Dysregulated neutrophil extracellular trap (NET) release has been proposed as a source of autoantigens in lupus. Furthermore, it has recently been shown that the…
Abstract Number: 107 • 2018 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants, Renal Histopathology, and Prognosis in African American SLE Nephritis Patients: A Cohort Study
Ashira Blazer¹, Ming Wu², Nancyanne Schmidt³, Alana Engelbrecht⁴, Feng-Xia Liang⁵, Robert M. Clancy⁶, Jill P. Buyon⁷ and H. Michael Belmont⁸, ¹Internal Medicine Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Pathology, New York University, New York, NY, ³Internal Medicine, New York University School of Medicine, New York, NY, ⁴Rheumatology, NYU Langone Health, New York, NY, ⁵Office of Science and Research, New York University School of Medicine, New York, NY, ⁶Colton Center for Autoimmunity, New York University, New York, NY, ⁷Rheumatology, NYU School of Medicine, New York, NY, ⁸Division of Rheumatology, New York University, New York, NY
Background/Purpose: Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, associate with CKD in African Americans (AA) and are evolutionarily preserved due to improved infectious…
Abstract Number: 463 • 2018 ACR/ARHP Annual Meeting
Percentage of Glomerular Crescents Predicts Renal Outcomes in Childhood-Onset Lupus Nephritis
Pooja Patel¹, Marietta M. De Guzman¹, Joseph Maliakkal², Michelle Rheault³, David Selewski⁴, Katherine Twombley⁵, Jason Misurac⁶, Cheryl Tran⁷, Alexandru Constantinescu⁸, Ali Mirza Onder⁹, Meredith Seamon¹⁰, Vaishali Singh¹¹, Cynthia Pan¹¹, Joseph Flynn¹², Abiodun Omoloja¹³, William Smoyer¹⁴, Guillermo Hidalgo¹⁵ and Scott E. Wenderfer¹⁶, ¹Pediatrics-Rheumatology, Baylor College of Medicine, Houston, TX, ²Pediatrics-Renal, Saint Louis University, St. Louis, MO, ³Pediatrics-Renal, University of Minnesota, Minneapolis, MN, ⁴Pediatrics-Renal, University of Michigan, Ann Arbor, MI, ⁵Pediatrics-Renal, Medical University of South Carolina, Charleston, SC, ⁶Pediatrics-Renal, University of Iowa, Iowa City, IA, ⁷Pediatrics-Renal, Mayo Clinic, Rochester, MN, ⁸Pediatrics-Renal, Joe DiMaggio Children’s Hospital, Hollywood, FL, ⁹Pediatrics-Renal, University of Tennessee, Memphis, TN, ¹⁰Pediatrics-Renal, The University of Utah, Salt Lake, UT, ¹¹Pediatrics-Renal, Medical College of Wisconsin, Wauwatosa, WI, ¹²Pediatrics-Renal, Seattle Children's Hospital, Seattle, WA, ¹³Pediatrics-Renal, Wright State University, Dayton, OH, ¹⁴Pediatrics-Renal, Nationwide Children’s Hospital, Columbus, OH, ¹⁵Pediatrics-Renal, East Carolina University, Greenville, NC, ¹⁶Pediatrics-Renal, Baylor College of Medicine, Houston, TX
Background/Purpose: Outcomes for childhood-onset crescentic lupus nephritis are unclear. The revised classification system for lupus nephritis by the Renal Pathology Society clearly distinguishes between cellular,…
Abstract Number: 757 • 2018 ACR/ARHP Annual Meeting
Urinary Galectin-3 Binding Protein As a Novel Biomarker of Renal Disease Activity in Lupus Nephritis
Huihua Ding¹, Cheng Ling², Roberto Bassi³, Shinji L Okitsu⁴, Julie A. DeMartino⁴ and Nan Shen¹, ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Department of Rheumatology, Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴TIP Immunology, EMD Serono Research and Development Institute, Inc., Billerica, MA
Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestations of systemic lupus erythematosus (SLE). This study investigates urinary galecting-3 binding protein…
Abstract Number: 832 • 2018 ACR/ARHP Annual Meeting
Immunoglobuline a Vasculitis: Comparison between Pediatric and Adult Population
Martin Brom¹, Ignacio Javier Gandino², Marina Scolnik³, Valeria Scaglioni³, Maria Britos⁴, Carmen De Cunto⁴ and Enrique R Soriano³, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ⁴Pediatric Rheumatology, Hospital Italiano De Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Immunoglobuline A (IgA) Vasculitis, formerly known as Henoch-Schönlein purpura, is a small-vessel leukocytoclastic vasculitis due to deposition of IgA1, a subclass of IgA. Although…
Abstract Number: 2230 • 2018 ACR/ARHP Annual Meeting
Serum Urate Levels in People with Gout on Dialysis – Are We Achieving Treatment Targets?
Estella Yeo¹, Suetonia Palmer², Peter T. Chapman³, Christopher Frampton⁴ and Lisa K. Stamp⁴, ¹Canterbury District Health Board, Christchurch, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³Christchurch Hospital, Christchurch, New Zealand, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: To explore the number of patients on haemodialysis (HD) or peritoneal dialysis (PD) with gout in Canterbury and to determine how many were receiving…
Abstract Number: 2232 • 2018 ACR/ARHP Annual Meeting
Prevalence of Gout in the Surviving U.S. Solid Organ Transplant Population
Mark D. Brigham¹, Thilan Tudor¹, Gavin Miyasato¹, Jeffrey D. Kent², Brian LaMoreaux³ and Brian F. Mandell⁴, ¹Trinity Partners, Waltham, MA, ²Medical Affairs, Horizon Pharma USA, Inc, Lake Forest, IL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Although incidence and survival are frequent topics within the solid organ transplant (SOT) literature, there are no recent publications on the total size of…
Abstract Number: 2242 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease
William B. White¹ and Lhanoo Gunawardhana², ¹Cardiology, University of Connecticut School of Medicine, Farmington, CT, ²Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: The Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Comorbidities (CARES) trial demonstrated that major cardiovascular (CV) outcomes on febuxostat…
Abstract Number: 2948 • 2018 ACR/ARHP Annual Meeting
Deconstructing the in Situ Myeloid Cell Microenvironment in Human Lupus Nephritis Tissue
Paul Hoover^1,2, Tony Jones², Cianna Leatherwood³, Sushrut Waikar⁴, Karen Costenbader³ and Nir Hacohen⁵, ¹Division of Rheumatology, Allergy, Immunology, Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Cambridge, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Renal, Brigham and Women's Hospital, Boston, MA, ⁵Harvard Medical School, Boston, MA
Background/Purpose: The cell-types and pathways driving lupus nephritis (LN) are incompletely understood. The Accelerating Medicine Partnership lupus network Pathway Exploration and Analysis in RenaL disease…
Abstract Number: 322 • 2017 ACR/ARHP Annual Meeting
Safety of Denosumab in a Monocentric Cohort of Kidney Transplant Recipients
Sonia Doddoli, Pierre Lafforgue and Thao Pham, Rheumatology, APHM, Aix Marseille Univ, Marseille, France
Background/Purpose: Safety of denosumab, a fully human monoclonal antibody against RANKL developed for osteoporosis and prevention of fracture remains unclear in kidney transplanted patients. A…
Abstract Number: 1026 • 2017 ACR/ARHP Annual Meeting
Gene Expression Analysis Reveals Common Pathways of Tissue Pathogenesis in Lupus Organ Involvement
Amrie Grammer¹, Sarah Heuer¹, Robert Robl¹, Adam Labonte¹, Prathyusha Bachali¹, Sushma Madamanchi¹ and Peter E. Lipsky², ¹AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Lupus is a prototypic autoimmune disease characterized by B cell hyperactivity, autoantibody formation and resultant tissue damage. The mechanisms underlying tissue pathology in lupus…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].